

Pierre F Desreumaux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5328285/publications.pdf>

Version: 2024-02-01

254
papers

24,255
citations

10956

71
h-index

7496

151
g-index

274
all docs

274
docs citations

274
times ranked

20414
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1269-1280.	0.6	15
2	Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 832-840.	1.4	11
3	<i>Saccharomyces cerevisiae</i> 3856 in irritable bowel syndrome with predominant constipation. <i>World Journal of Gastroenterology</i> , 2022, 28, 2509-2522.	1.4	10
4	Adherent invasive <i>Escherichia coli</i> (AIEC) strain LF82, but not <i>Candida albicans</i> , plays a profibrogenic role in the intestine. <i>Gut Pathogens</i> , 2021, 13, 5.	1.6	6
5	A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of <i>Candida</i> Yeasts and Fluconazole in Crohn's Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 324.	1.5	9
6	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. <i>PLoS ONE</i> , 2021, 16, e0257281.	1.1	5
7	Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1445-1452.	1.1	23
8	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1272-1274.	4.8	4
9	Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the LÃ©mann Index and Inflammatory Bowel Disease Disability Index. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 889-898.	1.9	21
10	Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 394-402.	0.9	17
11	Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 847-856.	2.4	23
12	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). <i>Gut</i> , 2019, 68, 40-48.	6.1	132
13	IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 1910-1925.	3.9	85
14	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 892-899.e2.	2.4	80
15	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 485-493.	1.9	91
16	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating $\gamma\delta^+$ T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	0.6	24
17	Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses. <i>PLoS ONE</i> , 2018, 13, e0209681.	1.1	15
18	Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1247-1252.	0.8	23

#	ARTICLE	IF	CITATIONS
19	Male gender, active smoking and previous intestinal resection are risk factors for postoperative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 924-932.	1.9	71
20	High carriage of adherent invasive <i>E. coli</i> in wildlife and healthy individuals. <i>Gut Pathogens</i> , 2018, 10, 23.	1.6	14
21	<i>Neoboutonia melleri</i> var <i>velutina</i> Prain: in vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 24.	3.7	1
22	Postoperative complications in elderly onset inflammatory bowel disease: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1652-1660.	1.9	12
23	Bacteriophages targeting adherent invasive <i>Escherichia coli</i> strains as a promising new treatment for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw224.	0.6	102
24	Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. <i>Digestive and Liver Disease</i> , 2017, 49, 163-169.	0.4	15
25	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 310-321.	1.9	128
26	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 533-541.	1.9	35
27	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017, 112, 337-345.	0.2	138
28	Peroxisome proliferator-activated receptor gamma (PPAR γ) regulates lactase expression and activity in the gut. <i>EMBO Molecular Medicine</i> , 2017, 9, 1471-1481.	3.3	16
29	Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1853-1859.	0.9	23
30	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. <i>Gut</i> , 2017, 66, 1912-1917.	6.1	24
31	The Presence of Adherent-Invasive <i>Escherichia Coli</i> (AIEC) on the Surgical Specimen is a Predictor of Severe Endoscopic Postoperative Recurrence in Ileal Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S9.	0.6	1
32	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1326-1334.	0.6	19
33	Trough Levels and Antibodies to Ustekinumab are not Correlated to Response to Ustekinumab Treatment in Crohn's Disease Patients. <i>Gastroenterology</i> , 2017, 152, S388.	0.6	2
34	The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2017, 8, 1052.	2.2	13
35	<i>Saccharomyces cerevisiae</i> CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. <i>World Journal of Gastroenterology</i> , 2017, 23, 336.	1.4	43
36	Role of glycogen synthase kinase-3 β and PPAR γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. <i>PLoS ONE</i> , 2017, 12, e0171093.	1.1	35

#	ARTICLE	IF	CITATIONS
37	Effects of urban coarse particles inhalation on oxidative and inflammatory parameters in the mouse lung and colon. <i>Particle and Fibre Toxicology</i> , 2017, 14, 46.	2.8	49
38	Anti-Inflammatory Effect of Recombinant Human Alpha-fetoprotein (rhAFP) in the Model of TNBS-induced Colitis. <i>American Journal of Gastroenterology</i> , 2017, 112, S375-S376.	0.2	1
39	Probiotic Yeast Therapy for Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 542-542.	0.8	2
40	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 252-261.	1.9	111
41	OC-005â€¦A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohnâ€™s Disease (CD) Refractory to anti-TNFÎ±: UNITI-1. <i>Gut</i> , 2016, 65, A3.2-A4.	6.1	0
42	Gut: An underestimated target organ for Aluminum. <i>Morphologie</i> , 2016, 100, 75-84.	0.5	32
43	O-001â€¦A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnâ€™s Disease Refractory to Anti-TNFÎ±. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S1.	0.9	42
44	Mo1909 Adalimumab Dose Escalation Is Effective and Well Tolerated in Crohn's Disease Patients With Secondary Loss of Response to Adalimumab. <i>Gastroenterology</i> , 2016, 150, S813-S814.	0.6	0
45	Mo1899 Evaluation and Long-Term Benefit of Deep Remission in Crohn's Disease Patients Treated With Infliximab. <i>Gastroenterology</i> , 2016, 150, S810-S811.	0.6	1
46	979 Modulating Peroxisome Proliferator-Activated Receptor Gamma (PPARÎ³): A Potential New Therapeutic Strategy for Lactose Intolerance. <i>Gastroenterology</i> , 2016, 150, S199.	0.6	0
47	Mo1900 Combination Therapy With Infliximab and Methotrexate Does Not Improve Crohn's Disease Outcome and Infliximab Tolerance Compared to Infliximab Therapy Alone. <i>Gastroenterology</i> , 2016, 150, S811.	0.6	0
48	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168
49	Toxicological consequences of experimental exposure to aluminum in human intestinal epithelial cells. <i>Food and Chemical Toxicology</i> , 2016, 91, 108-116.	1.8	30
50	Mo1823 Highlighting of Epidemic Areas of Crohn's Disease in a Population-Based Registry Over 22 Years: Genetic or Environmental Cause?. <i>Gastroenterology</i> , 2016, 150, S785-S786.	0.6	0
51	Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohnâ€™s Disease Patients Classified I2 on the Rutgeerts Score. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2986-2992.	1.1	34
52	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohnâ€™s Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jcw151.	0.6	17
53	Ustekinumab as Induction and Maintenance Therapy for Crohnâ€™s Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1946-1960.	13.9	1,316
54	Novel PPARÎ³ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 279-292.	0.9	68

#	ARTICLE	IF	CITATIONS
55	Mo1898 Continuation or Switch to Another Anti-TNF± After Intestinal Resection in Crohn's Disease Patients Previously Exposed to Anti-TNF±?. <i>Gastroenterology</i> , 2016, 150, S810.	0.6	0
56	Sa1846 The Expression of the Short Isoform of TSLP in the Colon Is Regulated by the Nuclear Receptor PPAR ^β and Is Impaired During Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S379.	0.6	0
57	Sa1960 Crohn's Disease Patients With High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. <i>Gastroenterology</i> , 2016, 150, S417.	0.6	2
58	Su1868 Dissecting the Role of RAGE in Intestinal Fibrosis. <i>Gastroenterology</i> , 2016, 150, S575.	0.6	0
59	Tu1881 HLA B27 Transgenic Rat: A New Animal Model of Postsurgical Ileitis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S967.	0.6	1
60	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. <i>Gastroenterology</i> , 2016, 150, S155.	0.6	6
61	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	0.6	251
62	The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils. <i>Mucosal Immunology</i> , 2016, 9, 322-335.	2.7	43
63	Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. <i>Scientific Reports</i> , 2015, 5, 9577.	1.6	45
64	The role of PPAR ^γ -mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology. <i>Experimental Dermatology</i> , 2015, 24, 245-251.	1.4	79
65	Intestinal steroidogenesis. <i>Steroids</i> , 2015, 103, 64-71.	0.8	32
66	A randomized clinical trial of <i>Saccharomyces cerevisiae</i> versus placebo in the irritable bowel syndrome. <i>Digestive and Liver Disease</i> , 2015, 47, 119-124.	0.4	103
67	Author's reply to Comment on "A randomized clinical trial of <i>Saccharomyces cerevisiae</i> versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [<i>Digestive and Liver Disease</i> 2015;47:119-124]. <i>Digestive and Liver Disease</i> , 2015, 47, 437-438.	0.4	0
68	Intestinal steroidogenesis controls PPAR ^β expression in the colon and is impaired during ulcerative colitis. <i>Gut</i> , 2015, 64, 901-910.	6.1	47
69	Eosinophilic Enteritis. <i>Digestive Diseases</i> , 2015, 33, 183-189.	0.8	22
70	Superantigenic <i>Yersinia pseudotuberculosis</i> Induces the Expression of Granzymes and Perforin by CD4 + T Cells. <i>Infection and Immunity</i> , 2015, 83, 2053-2064.	1.0	13
71	Acrylamide induces accelerated endothelial aging in a human cell model. <i>Food and Chemical Toxicology</i> , 2015, 83, 140-145.	1.8	12
72	Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 198-203.	1.3	23

#	ARTICLE	IF	CITATIONS
73	In vivo efficacy of microbiota-sensitive coatings for colon targeting: A promising tool for IBD therapy. <i>Journal of Controlled Release</i> , 2015, 197, 121-130.	4.8	34
74	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. <i>Mucosal Immunology</i> , 2014, 7, 589-601.	2.7	78
75	Peroxisome Proliferator-activated Receptor Gamma in the Colon. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S23-S27.	1.1	20
76	Mo1696 Treatment With P28GST, a Recombinant Enzyme From Schistosome Helminth Parasite Prevents Hapten-Induced Colitis by Inducing a Regulatory Th2 Response. <i>Gastroenterology</i> , 2014, 146, S-638.	0.6	0
77	Switching cannabinoid response from CB2 agonists to FAAH inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1322-1326.	1.0	12
78	Preclinical Studies of a Specific PPAR γ Modulator in the Control of Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1001-1011.	0.3	44
79	Evaluation of therapeutic properties of fermented vegetables extract (OM-X \hat{A}) in the model of colitis induced by <i>Citrobacter rodentium</i> in mice. <i>Journal of Functional Foods</i> , 2014, 10, 117-127.	1.6	9
80	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	6.1	122
81	Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G274-G285.	1.6	60
82	P084 Dissecting the role of PPAR γ in intestinal fibrosis: EMT-activator ZEB1 as new molecular target. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S97.	0.6	0
83	OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S4-S5.	0.6	9
84	Switching Invariant Natural Killer T (iNKT) Cell Response from Anticancerous to Anti-Inflammatory Effect: Molecular Bases. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5489-5508.	2.9	62
85	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5383-5394.	1.4	36
86	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2013, 369, 711-721.	13.9	2,001
87	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2013, 369, 699-710.	13.9	2,114
88	One year multiple injections of antigen specific T regulatory lymphocytes in refractory crohn's disease patients, extension of CATS1 study. <i>Cytotherapy</i> , 2013, 15, S42.	0.3	0
89	Virtual Screening of CB ₂ Receptor Agonists from Bayesian Network and High-Throughput Docking: Structural Insights into Agonist-Modulated GPCR Features. <i>Chemical Biology and Drug Design</i> , 2013, 81, 442-454.	1.5	19
90	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPAR γ . <i>Carcinogenesis</i> , 2013, 34, 2580-2586.	1.3	30

#	ARTICLE	IF	CITATIONS
91	Functional Polymorphisms in the Regulatory Regions of the VNN1 Gene Are Associated with Susceptibility to Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2315-2325.	0.9	38
92	<i>In vivo</i> imaging reveals selective PPAR activity in the skin of peroxisome proliferator-activated receptor responsive element-luciferase reporter mice. <i>Experimental Dermatology</i> , 2013, 22, 137-140.	1.4	10
93	Decreased Lymphatic Vessel Density Is Associated With Postoperative Endoscopic Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2084-2090.	0.9	48
94	Colonic Inflammation in Mice Is Improved by Cigarette Smoke through iNKT Cells Recruitment. <i>PLoS ONE</i> , 2013, 8, e62208.	1.1	30
95	PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention. <i>Current Drug Targets</i> , 2013, 14, 1501-1507.	1.0	52
96	Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. <i>Gut</i> , 2012, 61, 78-85.	6.1	210
97	Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents. <i>Current Medicinal Chemistry</i> , 2012, 19, 3457-3474.	1.2	33
98	4-Oxo-1,4-dihydropyridines as Selective CB ₂ Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8948-8952.	2.9	21
99	GW501516-activated PPAR α promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. <i>Cell and Bioscience</i> , 2012, 2, 34.	2.1	63
100	Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease. <i>Gastroenterology</i> , 2012, 143, 1207-1217.e2.	0.6	323
101	Mucin 20 Mucin Cys Domain Strengthens the Mucus Barrier During Experimental Intestinal Inflammation. <i>Gastroenterology</i> , 2012, 142, S-721-S-722.	0.6	0
102	Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1199-1206.	0.9	105
103	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2063-2071.	0.9	96
104	AIEC colonization and pathogenicity: Influence of previous antibiotic treatment and preexisting inflammation. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1923-1931.	0.9	35
105	Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4027-4061.	2.9	160
106	Visceral fat and gut inflammation. <i>Nutrition</i> , 2012, 28, 113-117.	1.1	62
107	Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 430-438.	0.9	20
108	Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo. <i>Gastroenterology</i> , 2011, 140, S-515.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Glucagon Like Peptide 2 (GLP2) Receptor Expression is Not Restricted to the Gastrointestinal Tract and is Modulated by Inflammation. <i>Gastroenterology</i> , 2011, 140, S-477.	0.6	0
110	Early Involvement of Liver Natural Killer T Cells in Limiting Colonic Inflammation and Application to Disease Treatment. <i>Gastroenterology</i> , 2011, 140, S-1.	0.6	1
111	<i>Saccharomyces Cerevisiae</i> CNCM I-3856 Reduces Digestive Discomfort and Abdominal Pain in Subjects With Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo-Controlled Clinical Trial. <i>Gastroenterology</i> , 2011, 140, S-50.	0.6	4
112	Natural History of Eosinophilic Gastroenteritis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 950-956.e1.	2.4	171
113	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 141, 1621-1628.e5.	0.6	431
114	Aluminum Enhances Inflammation and Decreases Healing in Experimental Models of Colitis. <i>Gastroenterology</i> , 2011, 140, S-493.	0.6	0
115	Antibiotics Induced Commensal Flora Disruption Favours <i>Escherichia coli</i> AIEC (LF82) Colonization in Wild Type and NOD2 Knock-out Mice. <i>Gastroenterology</i> , 2011, 140, S-324.	0.6	0
116	Clinical Value of Measuring Trough Levels and Human Anti-Chimeric Antibodies in Patients With Inflammatory Bowel Disease Who Lost Response to Infliximab Therapy. <i>Gastroenterology</i> , 2011, 140, S-277.	0.6	1
117	Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 533-543.	1.9	81
118	Using a Sodar to Measure Optical Turbulence and Wind Speed for the Thirty Meter Telescope Site Testing. Part I: Reproducibility. <i>Boundary-Layer Meteorology</i> , 2011, 141, 273-288.	1.2	6
119	Peas starch-based film coatings for site-specific drug delivery to the colon. <i>Journal of Applied Polymer Science</i> , 2011, 119, 1176-1184.	1.3	18
120	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3777-3786.	1.4	38
121	Obesity, visceral fat and Crohn's disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2010, 13, 574-580.	1.3	77
122	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8772-8777.	3.3	183
123	Enzymatically activated coated multiparticulates containing theophylline for colon targeting. <i>Journal of Drug Delivery Science and Technology</i> , 2010, 20, 193-199.	1.4	10
124	4-Oxo-1,4-dihydropyridines as Selective CB ₂ Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7918-7931.	2.9	30
125	274 <i>Sacharomyces Cerevisiae</i> Cncm I-3856 Decreases Intestinal Pain Through PPAR Alpha Activation in the Gut. <i>Gastroenterology</i> , 2010, 138, S-51.	0.6	3
126	Neutrophil Migration During Liver Injury Is Under Nucleotide-Binding Oligomerization Domain 1 Control. <i>Gastroenterology</i> , 2010, 138, 1546-1556.e5.	0.6	32

#	ARTICLE	IF	CITATIONS
127	Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti-Tumor Necrosis Factor Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1048-1055.	2.4	158
128	Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 1676-1684.	1.2	18
129	Characterization of ethylcellulose: starch-based film coatings for colon targeting. <i>Drug Development and Industrial Pharmacy</i> , 2009, 35, 1190-1200.	0.9	15
130	Novel polymeric film coatings for colon targeting: Drug release from coated pellets. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 37, 427-433.	1.9	56
131	PPAR α agonists as a new class of effective treatment for ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 959-960.	0.9	6
132	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1476-1484.	0.9	59
133	Novel polymeric film coatings for colon targeting: How to adjust desired membrane properties. <i>International Journal of Pharmaceutics</i> , 2009, 371, 64-70.	2.6	25
134	Colon targeting with bacteria-sensitive films adapted to the disease state. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 73, 74-81.	2.0	31
135	703 BACTERIAL RECEPTOR NOD1 REGULATES THE NEUTROPHIL MIGRATION MACHINERY DURING LIVER INJURY. <i>Journal of Hepatology</i> , 2009, 50, S258.	1.8	0
136	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Lancet, The</i> , 2009, 374, 1617-1625.	6.3	996
137	Short-term variability of intertidal microphytobenthic production using an oxygen microprofiling system. <i>Marine and Freshwater Research</i> , 2009, 60, 712.	0.7	16
138	Resistin-like molecule β 2 regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 931-941.	0.9	82
139	NOD2: a potential target for regulating liver injury. <i>Laboratory Investigation</i> , 2008, 88, 318-327.	1.7	41
140	740 Development of a New Optimized 5-ASA Molecule Ged-0507-34 with Intestinal Anti-Inflammatory and Analgesic Properties. <i>Gastroenterology</i> , 2008, 134, A-106-A-107.	0.6	1
141	741 4-Oxo-1,4-Dihydroquinoline-3-Carboxamides Derivatives As New Potent and Selective Cb2 Agonists with Anti-Inflammatory and Analgesic Properties in the Gut. <i>Gastroenterology</i> , 2008, 134, A-107.	0.6	3
142	Crohn's disease: beyond antagonists of tumour necrosis factor. <i>Lancet, The</i> , 2008, 372, 67-81.	6.3	100
143	Colonization of Mice by <i>Candida albicans</i> Is Promoted by Chemically Induced Colitis and Augments Inflammatory Responses through Galectin-3. <i>Journal of Infectious Diseases</i> , 2008, 197, 972-980.	1.9	161
144	Understanding the Mechanism of 5-ASA in Treating Colonic Inflammation. <i>Gastroenterology and Hepatology</i> , 2008, 4, 319-20.	0.2	2

#	ARTICLE	IF	CITATIONS
145	Î-Opioid receptor activation prevents acute hepatic inflammation and cell death. <i>Gut</i> , 2007, 56, 974-981.	6.1	27
146	Vascular and Cellular Stress in Inflammatory Bowel Disease: Revisiting the Role of Homocysteine. <i>American Journal of Gastroenterology</i> , 2007, 102, 1108-1115.	0.2	49
147	Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. <i>Gut</i> , 2007, 56, 577-583.	6.1	200
148	LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13098-13103.	3.3	136
149	[30] INVOLVEMENT OF NOD SIGNALLING IN HEPATOCYTE AND IMMUNE CELLS DURING HEPATITIS. <i>Journal of Hepatology</i> , 2007, 46, S15.	1.8	0
150	CEACAM6 acts as a receptor for adherent-invasive <i>E. coli</i> , supporting ileal mucosa colonization in Crohn disease. <i>Journal of Clinical Investigation</i> , 2007, 117, 1566-1574.	3.9	490
151	How NOD2 mutations predispose to Crohn's disease?. <i>Microbes and Infection</i> , 2007, 9, 658-663.	1.0	34
152	<i>Lactobacillus acidophilus</i> modulates intestinal pain and induces opioid and cannabinoid receptors. <i>Nature Medicine</i> , 2007, 13, 35-37.	15.2	734
153	Adherent-invasive <i>Escherichia coli</i> isolated from Crohn's disease patients induce granulomas in vitro. <i>Cellular Microbiology</i> , 2007, 9, 1252-1261.	1.1	115
154	Search for evidence of recurring or persistent viruses in Crohn's disease. <i>Apmis</i> , 2007, 115, 962-968.	0.9	22
155	Advances and Perspectives in the Genetics of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 143-151.	2.4	29
156	Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions. <i>Gastroenterology</i> , 2006, 130, 1962-1974.	0.6	117
157	CD8+ Cytotoxic T Cells Induce Relapsing Colitis in Normal Mice. <i>Gastroenterology</i> , 2006, 131, 485-496.	0.6	93
158	NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. <i>Trends in Microbiology</i> , 2006, 14, 432-438.	3.5	44
159	PPARÎ³. <i>Inflammatory Bowel Diseases</i> , 2006, 12, S9-S10.	0.9	0
160	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 851-858.	1.9	32
161	Review article: mode of action and delivery of 5-aminosalicylic acid â€“ new evidence. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 2-9.	1.9	233
162	No Evidence for an Involvement of the P38 and JNK Mitogen-Activated Protein in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1443-1453.	1.1	28

#	ARTICLE	IF	CITATIONS
163	PPAR α as a new therapeutic target in inflammatory bowel diseases. <i>Gut</i> , 2006, 55, 1341-1349.	6.1	363
164	Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. <i>Gut</i> , 2006, 55, 815-823.	6.1	80
165	Infliximab failure in cap polyposis. <i>Gut</i> , 2005, 54, 313-314.	6.1	26
166	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor- β . <i>Journal of Experimental Medicine</i> , 2005, 201, 1205-1215.	4.2	428
167	Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. <i>Gastroenterology</i> , 2005, 128, 334-342.	0.6	194
168	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 309.	1.4	56
169	Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor β and carnitine palmitoyl acyl-CoA transferase 1A. <i>World Journal of Gastroenterology</i> , 2005, 11, 7591.	1.4	66
170	<i>Yersinia pseudotuberculosis</i> Anti-Inflammatory Components Reduce Trinitrobenzene Sulfonic Acid-Induced Colitis in the Mouse. <i>Infection and Immunity</i> , 2004, 72, 2438-2441.	1.0	11
171	Dysbiosis in inflammatory bowel disease. <i>Gut</i> , 2004, 53, 1-4.	6.1	693
172	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. <i>Transplantation</i> , 2004, 78, 1697-1701.	0.5	64
173	Macrophage collections in gastrointestinal biopsies and metabolic disorders: two unusual case reports. <i>Histopathology</i> , 2003, 42, 196-198.	1.6	2
174	Probiotics in inflammatory bowel disease: a critical review. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 805-820.	1.0	60
175	No evidence for involvement of the mitogen-activated protein kinase (MAPK) P38 and JNK pathways in human inflammatory bowel diseases and experimental colitis. <i>Gastroenterology</i> , 2003, 124, A326-A327.	0.6	0
176	Impaired expression of peroxisome proliferator-activated receptor β in ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, 1265-1276.	0.6	370
177	Stress-induced disruption of colonic epithelial barrier: role of interferon- β and myosin light chain kinase in mice. <i>Gastroenterology</i> , 2003, 125, 795-804.	0.6	182
178	Use of Mouse Models To Evaluate the Persistence, Safety, and Immune Modulation Capacities of Lactic Acid Bacteria. <i>Vaccine Journal</i> , 2003, 10, 696-701.	3.2	113
179	Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. <i>Gut</i> , 2003, 52, 840-846.	6.1	130
180	Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. <i>European Journal of Anaesthesiology</i> , 2003, 20, 957-962.	0.7	5

#	ARTICLE	IF	CITATIONS
181	Impact of the <i>Yersinia pseudotuberculosis</i> -Derived Mitogen (YPM) on the Murine Immune System. , 2003, 529, 133-135.		2
182	Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation. <i>Journal of Clinical Investigation</i> , 2003, 111, 1329-1338.	3.9	84
183	Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation. <i>Journal of Clinical Investigation</i> , 2003, 111, 1329-1338.	3.9	144
184	Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. <i>Gastroenterologie Clinique Et Biologique</i> , 2003, 27, 987-91.	0.9	107
185	Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 939-946.	0.2	240
186	Binding of <i>Escherichia coli</i> adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2977-2982.	3.3	213
187	Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. <i>Gut</i> , 2002, 50, 25-28.	6.1	58
188	Role of peroxisome proliferator-activated receptor β and retinoid X receptor heterodimer in hepatogastroenterological diseases. <i>Lancet, The</i> , 2002, 360, 1410-1418.	6.3	181
189	ThÃ©rapeutique nutritionnelle des maladies inflammatoires chroniques de lâ€™intestin. <i>Nutrition Clinique Et Metabolisme</i> , 2002, 16, 202-205.	0.2	1
190	Epithelial inflammation response induced by <i>Shigella flexneri</i> depends on mucin gene expression. <i>Microbes and Infection</i> , 2002, 4, 1121-1124.	1.0	36
191	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. <i>Leukemia</i> , 2002, 16, 1637-1644.	3.3	45
192	Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 739-741.	1.5	11
193	CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease. <i>Human Immunology</i> , 2001, 62, 694-700.	1.2	9
194	A Unique PPAR β Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity. <i>Molecular Cell</i> , 2001, 8, 737-747.	4.5	279
195	Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. <i>Gut</i> , 2001, 49, 42-46.	6.1	212
196	Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (R α r)/Peroxisome Proliferator-Activated Receptor β (Ppar β) Heterodimer. <i>Journal of Experimental Medicine</i> , 2001, 193, 827-838.	4.2	416
197	Pyrogenicity and Cytokine-Inducing Properties of <i>Streptococcus pyogenes</i> Superantigens: Comparative Study of Streptococcal Mitogenic Exotoxin Z and Pyrogenic Exotoxin A. <i>Infection and Immunity</i> , 2001, 69, 4141-4145.	1.0	27
198	Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13306-13311.	3.3	273

#	ARTICLE	IF	CITATIONS
199	Role of the High Affinity Immunoglobulin E Receptor in Bacterial Translocation and Intestinal Inflammation. <i>Journal of Experimental Medicine</i> , 2001, 193, 25-34.	4.2	33
200	Genetically related <i>Escherichia coli</i> strains associated with Crohn's disease. <i>Gut</i> , 2001, 48, 320-325.	6.1	87
201	Mucin gene expression in intestinal epithelial cells in Crohn's disease. <i>Gut</i> , 2001, 49, 544-551.	6.1	139
202	Pouchitis Is Associated with Mucosal Imbalance Between Interleukin-8 and Interleukin-10. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 157-164.	0.9	42
203	Impaired contractile response of mesenteric arteries in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1279-1285.	1.9	7
204	Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). <i>Clinical and Experimental Immunology</i> , 2000, 122, 180-185.	1.1	31
205	Expression of peroxisome proliferator-activated receptor γ (PPAR γ) in normal human pancreatic islet cells. <i>Diabetologia</i> , 2000, 43, 1165-1169.	2.9	183
206	Systemic Administration of Agonist Peptide Blocks the Progression of Spontaneous CD8-Mediated Autoimmune Diabetes in Transgenic Mice Without Bystander Damage. <i>Journal of Immunology</i> , 2000, 165, 202-210.	0.4	24
207	Specific targeting of IL-6 signalling pathway: a new way to treat IBD?. <i>Gut</i> , 2000, 47, 465-466.	6.1	14
208	Chronic stress stimulates organ specific cytokine expression in mice. <i>Gastroenterology</i> , 2000, 118, A881.	0.6	0
209	Invasive ability of <i>Escherichia coli</i> strains isolated from ileal mucosa in Crohn's disease (CD). <i>Gastroenterology</i> , 2000, 118, A342.	0.6	4
210	Overexpression of leptin mRNA in the mesenteric adipose tissue of inflammatory bowel disease (IBD). <i>Gastroenterology</i> , 2000, 118, A340-A341.	0.6	9
211	Activation of PPAR γ protects against colon inflammation by inhibiting TNFA signaling pathways. <i>Gastroenterology</i> , 2000, 118, A864.	0.6	1
212	Laparoscopic surgery reduces perioperative opioid requirement in Crohn's disease. <i>Gastroenterology</i> , 2000, 118, A581.	0.6	0
213	Mesenteric adipose tissue: A major source of TNFA in experimental ileitis in rats. <i>Gastroenterology</i> , 2000, 118, A341.	0.6	0
214	IL-10 hepatic deficit in hepatitis C virus (HCV) infection. <i>Gastroenterology</i> , 2000, 118, A944.	0.6	0
215	Ige receptor affects fecal flora, bacterial translocation and intestinal inflammation. <i>Gastroenterology</i> , 2000, 118, A694.	0.6	0
216	Hepatic deficiency of interleukin 10 in chronic hepatitis C. <i>Gastroenterology</i> , 2000, 119, 1411-1412.	0.6	6

#	ARTICLE	IF	CITATIONS
217	Selective expansion of intraepithelial lymphocytes expressing the HLA-E α -specific natural killer receptor CD94 in celiac disease. <i>Gastroenterology</i> , 2000, 118, 867-879.	0.6	227
218	Low ileal IL-10 mRNA levels predict endoscopic recurrence in patients operated on for Crohn's disease (CD). <i>Gastroenterology</i> , 2000, 118, A108-A109.	0.6	0
219	453 Increased interleukin-10 and interleukin-4 mRNA expression in gut mucosa from patients with allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S149.	1.5	0
220	Infectious agents and Crohn's disease. <i>Clinical Microbiology and Infection</i> , 1999, 5, 601-604.	2.8	9
221	Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. <i>Gastroenterology</i> , 1999, 117, 73-81.	0.6	305
222	Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 1113-1120.	0.8	17
223	Abnormalities in Mucin Gene Expression in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 1999, 5, 24-32.	0.9	79
224	Transdermal Nicotine Decreases Mucosal IL-8 Expression but Has No Effect on Mucin Gene Expression in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 1999, 5, 174-181.	0.9	20
225	<title>Endoscopic fluorescence imaging for early assessment of anastomotic recurrence of Crohn's disease</title>. , 1999, , .		0
226	Similar IL-5, IL-3, and GM-CSF Syntheses by Eosinophils in the Jejunal Mucosa of Patients with Celiac Disease and Dermatitis Herpetiformis. <i>Clinical Immunology and Immunopathology</i> , 1998, 88, 14-21.	2.1	35
227	Activation of the peroxisome proliferator-activated receptor β promotes the development of colon tumors in C57BL/6J-APC ^{Min/+} mice. <i>Nature Medicine</i> , 1998, 4, 1053-1057.	15.2	568
228	Pathog \tilde{A} nie: aspects immunologiques, infectieux et g \tilde{A} ntiques. <i>Archives De Pediatrie</i> , 1998, 5, 97s-100s.	0.4	0
229	Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. <i>Gastroenterology</i> , 1998, 115, 1405-1413.	0.6	767
230	No bacteria detected by PCR in mesenteric lymph nodes from patients with Crohn's disease (CD). <i>Gastroenterology</i> , 1998, 114, A944-A945.	0.6	0
231	Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). <i>Gastroenterology</i> , 1998, 114, A958-A959.	0.6	5
232	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis (UC). <i>Gastroenterology</i> , 1998, 114, A1028.	0.6	8
233	IL-8 in early and chronic ileal lesions of Crohn's disease (CD). <i>Gastroenterology</i> , 1998, 114, A941.	0.6	0
234	Phenotypic changes of intraepithelial lymphocytes (IELS) in intestinal lesions of Crohn's disease (CD). <i>Gastroenterology</i> , 1998, 114, A968.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Mesenteric obesity in Crohn's disease (CD). <i>Gastroenterology</i> , 1998, 114, A989.	0.6	1
236	High level expression of PPAR β in differentiated colon epithelium. <i>Gastroenterology</i> , 1998, 114, A391.	0.6	0
237	Low ileal IL-10 mRNA levels may predict endoscopic recurrence after surgery in a subgroup of patients with Crohn's disease (CD). <i>Gastroenterology</i> , 1998, 114, A1038.	0.6	1
238	Mixed Adenocarcinoid Tumor and Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 353-354.	1.1	8
239	Streptococcal pyrogenic exotoxin A (SPE A) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells. <i>Microbial Pathogenesis</i> , 1997, 23, 265-272.	1.3	17
240	Immunobiology of eosinophils in allergy and inflammation. <i>Research in Immunology</i> , 1997, 148, 29-33.	0.9	11
241	Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. <i>Gastroenterology</i> , 1997, 113, 118-126.	0.6	212
242	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. <i>Gastroenterology</i> , 1996, 110, 768-774.	0.6	158
243	Eosinophils in allergic reactions. <i>Current Opinion in Immunology</i> , 1996, 8, 790-795.	2.4	67
244	Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. <i>Clinical and Experimental Immunology</i> , 1996, 104, 293-296.	1.1	2
245	Interferon- γ in combination with corticosteroids improves systemic mast cell disease. <i>British Journal of Dermatology</i> , 1995, 132, 479-482.	1.4	58
246	Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma.. <i>Journal of Experimental Medicine</i> , 1995, 182, 1897-1904.	4.2	99
247	Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease.. <i>Gut</i> , 1995, 37, 242-246.	6.1	100
248	Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis.. <i>Gut</i> , 1995, 37, 132-135.	6.1	6
249	Serosal vascular lesions in Crohn's disease. <i>Gastroenterology</i> , 1995, 108, A808.	0.6	0
250	Evidence for Eosinophil Activation in Eosinophilie Cystitis. <i>European Urology</i> , 1994, 25, 254-258.	0.9	34
251	Preliminary study of urinary schistosomiasis in a village in the delta of the Senegal river basin, Senegal. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 401-405.	0.7	38
252	Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion.. <i>Journal of Experimental Medicine</i> , 1994, 179, 703-708.	4.2	274

#	ARTICLE	IF	CITATIONS
253	Cerebro-Spinal Fluid Eosinophilia in Shunt Infections. <i>Neuropediatrics</i> , 1992, 23, 235-240.	0.3	27
254	Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease.. <i>Journal of Experimental Medicine</i> , 1992, 175, 293-296.	4.2	242